John H. Sampson

Duke University — United States

Medicine · Health Sciences

100h-index36.5kcitations722works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(296), Immunotherapy and Immune Responses(192), CAR-T cell therapy research(149), Cancer Immunotherapy and Biomarkers(113), Cancer Research and Treatments(82)

Publications706 total

Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma
JAMA Network Open·2025· 1 citedOpen Access
INNV-04. Association of proton pump inhibitor use with outcome of patients with newly diagnosed glioblastoma
Neuro-Oncology·2025Open Access
TIP-19. INTERROGATE-GBM Phase I trial: Immunotherapy peptide vaccine targeting cytomegalovirus (CMV) antigens in glioblastoma
Neuro-Oncology·2025Open Access
EXTH-68. Targeting Tumor Heterogeneity And Plasticity in Glioblastoma With Novel CAR T Cells Targeting PTPRZ1
Neuro-Oncology·2025Open Access
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma
Scientific Reports·2025· 1 citedOpen Access
OS04.3.A P30-EPS PEPTIDE VACCINE IS SAFE AND IMMUNOGENIC IN NEWLY DIAGNOSED GLIOBLASTOMA: A PHASE 1B TRIAL
Neuro-Oncology·2025Open Access
23OResults from 15 mg/kg single dose PGN-EDODM1 cohort of FREEDOM-DM1- a phase 1 study in people with myotonic dystrophy type 1 (DM1)
Neuromuscular Disorders·2025
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial
Nature Cancer·2025· 8 cited
IL-12 Secreting CAR-T Cells Reprogram the Tumor Microenvironment and Improve Efficacy Against Heterogeneous Models of Glioblastoma
2025· 1 citedOpen Access
Abstract CT057: Evaluation of tumor associated P30-peptide antigen (ETAPA): Safety and immunogenicity in a phase 1b trial in glioblastoma
Cancer Research·2025
IL-7–mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models
Journal of Clinical Investigation·2025· 5 citedOpen Access
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma
2025Open Access
Advances in neuro-oncology: contributions of the Asilomar Conference on brain tumor research and therapy
Journal of neurosurgery·2024
TMIC-45. CYTOMEGALOVIRUS PP65 ANTIGEN EXPRESSION FOLLOWING PP65-SPECIFIC DENDRITIC CELL VACCINATION IN MATCHED PRIMARY AND RECURRENT GLIOBLASTOMA SPECIMENS
Neuro-Oncology·2024Open Access
IMMU-52. A NOVEL MHC-INDEPENDENT MECHANISM FOR CD8+ T CELL KILLING
Neuro-Oncology·2024Open Access
CTIM-01. OUTCOMES AND IMMUNE RESPONSES AFTER PEPTIDE VACCINATION TARGETING HUMAN CYTOMEGALOVIRUS ANTIGEN PP65 IN CHILDREN AND YOUNG ADULTS WITH RECURRENT HIGH-GRADE GLIOMA AND MEDULLOBLASTOMA: RESULTS OF A PHASE 1 TRIAL
Neuro-Oncology·2024Open Access
IMMU-67. INTRACRANIAL IL12 SECRETING CAR-T CELLS OBVIATE THE NEED FOR LYMPHODEPLETION AND COMBAT HETEROGENEITY VIA MICROGLIAL INTERACTIONS
Neuro-Oncology·2024Open Access
IMMU-18. IL-7 MEDIATED UPREGULATION OF VLA-4 INCREASES ACCUMULATION OF ADOPTIVELY TRANSFERRED T LYMPHOCYTES IN MURINE GLIOMA
Neuro-Oncology·2024Open Access
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8 <sup>+</sup> infiltration in glioma
2024Open Access
Phase 2 study of bizaxofusp, an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm.
Journal of Clinical Oncology·2024
page 1 of 36Next →

Frequent Co-authors

Allan H. Friedman(25), David A. Reardon(23), Darell D. Bigner(23), Henry S. Friedman(23), James E. Herndon(22), Roger E. McLendon(18), Gary E. Archer(13), James J. Vredenburgh(12), Annick Desjardins(12), Jeremy N. Rich(10), Duane A. Mitchell(10), Jennifer A. Quinn(9), Sridharan Gururangan(8), Amy B. Heimberger(7), Michael Lim(6), James M. Provenzale(6), Robert J. Schmittling(5), Sandra Tourt-Uhlig(5), Luis Sánchez-Pérez(5), Sith Sathornsumetee(4)